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R. J. SHAW 
Department of Respirafoy Medicine, Imperial College School of Medicine at St. May’s, 
London, U.K. 
Overexuberant production of tumour necrosis factor-u (TNF-a) by macrophages and other cells is 
thought to contribute to the development of permanent lung damage in many inflammatory conditions. 
There is a need for an agent, without the side-effects of corticosteroids, which can reduce the production 
of TNF-a by macrophages activated by disease. This study evaluated the effect of thalidomide on 
lipopolysaccharide (LPS)-induced TNF-a production by human alveolar macrophages obtained from 
patients with tuberculosis and a group of other diseases associated with macrophage activation. 
Alveolar macrophages obtained by bronchoalveolar lavage from 3 1 patients (tuberculosis = 12, 
sarcoidosis= 3, lung cancer = 5, chronic bronchitis = 5, pneumonia = 6) were stimulated with LPS alone or 
LPS in combination with either thalidomide or dexamethasone. Cell-associated TNF-a, as measured by 
immunochemistry, and TNF-a released by macrophages, as assessed by ELISA, were markedly increased 
when cells were incubated with LPS (P<O.O5), and both were decreased following addition of 
thalidomide (P~0.05) or dexamethasone (PcO.05) to amounts similar to those observed when macro- 
phages were incubated with medium alone. Similarly, TNF-a mRNA as measured by in situ hybridiz- 
ation was increased following incubation with LPS (P<O*O5), but this increase was prevented by addition 
of thalidomide (PcO.05) or dexamethasone (PcO.05). The ability of thalidomide to reduce LPS-induced 
TNF-a production by alveolar macrophages was the same when cells from patients with tuberculosis (a 
disease associated with TNF-a production) and cells from patients with the other conditions were 
compared. 
The ability of thalidomide to reduce TNF-a production by human alveolar macrophages from patients 
with active lung disease suggests that thalidomide and its analogues may have potential as drugs to 
reduce TNF-a production in disease. 
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Introduction 
Tumour necrosis factor-a (TNF-a) derived from 
alveolar macrophages is thought to play a cen- 
tral role in the pathogenesis of many diseases 
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where tissue injury occurs as a result of an 
increased inflammatory response (l-l 1). The 
combined beneficial and detrimental role of 
TNF-a is highlighted in tuberculosis where there 
is evidence of increased local production of 
TNF-a (12), as well as an augmented ability of 
monocytes to produce TNF-a (13,14). Although 
TNF-a production is essential to mycobacterial 
killing (12,15-18), it may also contribute to 
weight loss and other clinical manifestations of 
the disease (14). In addition to promoting the 
inflammatory response, there is evidence that 
TNF-a is essential to the progression from in- 
flammation to fibrosis (6,19,20), a feature 
observed in chronic lung diseases such as 
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tuberculosis. In animal models of lung injury, the 
fibrotic reaction is almost completely prevented 
by administration of antibodies against TNF-a 
and is significantly increased by continuous 
infusion of recombinant TNF-a (35). 
In a search for therapeutic agents to reduce 
TNF-a, a number of drugs have been assessed. 
Corticosteroids reduce the amount of TNF-a 
released by human alveolar macrophages 
(4,21,22), but the drug needs to be given prior to 
the provoking stimulus and the effect may be 
stimulus-dependent (23), which might explain 
the variable effects of corticosteroids in some 
human diseases. Thalidomide (a-N-phthalyl- 
glutamic-acid-imine) has been used as an anti- 
inflammatory and immunosuppressive agent in 
rheumatoid arthritis, discoid lupus erythematous 
and graft vs. host disease (2427). Currently, it 
is used for the therapy of erythema nodosum 
leprosum, an acute inflammatory state occurring 
in lepromatous leprosy associated with the pro- 
duction of TNF-a, where it has been observed 
that TNF-a concentrations in serum are reduced 
after treatment of these patients with thalido- 
mide (25). Since it is known that thalidomide 
inhibits TNF-a protein synthesis by enhancing 
the degradation of TNF-a mRNA (8,27), a 
potential advantage of thalidomide might also 
be that the drug may be effective if given after 
the provoking stimulus has been applied. 
The present study asked whether thalidomide 
was as effective as corticosteroids in reducing 
TNF-a production by alveolar macrophages 
obtained from patients with lung diseases, in 
particular in tuberculosis where alveolar macro- 
phage TNF-a production is enhanced (19). 
Materials and Methods 
Patients with a range of diagnoses under- 
going diagnostic bronchoscopy were studied. 
Evaluation included chest roentgenogram and 
bronchoscopy with bronchoalveolar lavage. 
Patients gave their informed consent and the 
study was approved by the St. Mary’s Hospital 
Ethics Committee. 
BRONCHOALVEOLAR LAVAGE 
Bronchoalveolar lavage (BAL) was performed 
by standard techniques using an Olympus BF 
P20D flexible fibre-optic bronchoscope. Atro- 
pine with or without midazolam was used for 
pre-medication. Lignocaine (2%) was applied to 
the trachea as a local anaesthetic. Bronchoscopy 
was performed in the semi-erect position with 
supplemental oxygen, as required. After segmen- 
tal orifice inspection, the tip of the bronchoscope 
was wedged in the segmental orifice of the right 
middle lobe. Sterile saline at room temperature 
was instilled in 50-ml aliquots to a total of 
200 ml. The fluid was collected and aliquots were 
pooled in a 500-ml polypropylene bottle and 
placed on ice. 
MACROPHAGE ISOLATION AND 
STIMULATION 
After centrifugation (1000 rpm, 10 min) at room 
temperature, BAL cells were resuspended in 
medium RPM1 1640 containing 5 mM Hepes 
buffer (Gibco BRL, Renfrewshire, U.K.), 
100 U ml - ’ penicillin, 100 pg ml - ’ strepto- 
mycin (Gibco BRL) and 2 mM glutamine (Gibco 
BRL) to a final concentration of 1 x lo6 
cells ml - ‘. Cells were incubated at 37°C and 
5% CO, in tissue culture chamber glass slides 
(Lab tek, Nunc Inc., Naperville, U.S.A.) for 2 h. 
Non-adherent cells were then removed by 
sequential washes with medium RPM1 1640. 
Medium containing 100 U ml - ’ penicillin, 
lOOpurn ml- ’ streptomycin, 2 mM glutamine and 
10% fetal calf serum was added to the adherent 
macrophages. Cells were stimulated with 
lipopolysaccharide (LPS Escherichia coli 026:B6, 
Sigma Chemical Co., Dorset, U.K.) diluted 
in phosphate-buffered saline (PBS) at 1 or 
1Oymmll’ (25). Dexamethasone (Sigma 
Chemical Co.) at 1 mM ml - ’ (31) or thalidomide 
(Penn Pharm. Ltd, Gwent, U.K.) at 4yg ml - * 
(25) were added to the cells with LPS where 
indicated. Cell cultures were incubated at 37°C 
and 5% CO, for 24 or 48 h. Viability of the cells 
was tested by trypan blue exclusion test as per 
the manufacturer’s recommendations (Sigma 
Chemical Co.) and exceeded 90%. 
TNF-a EVALUATION 
After 24 and 48 h culture, the supernatants were 
collected and stored at - 20°C for ELISA assay. 
The slides were air-dried, fixed with either 
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acetone for immunocytochemistry to detect 
membrane-bound TNF, or 4% paraformalde- 
hyde for in situ hybridization, and stored at 
- 80°C. 
TNF-a Evaluation 
Slides were taken from - 8O”C, air-dried, fixed 
in acetone and washed in PBS (pH 7.2). Non- 
specific protein binding was blocked with 1: 10 
rabbit serum (Dako Ltd., Bucks, U.K.) in PBS. 
Primary antibody used in this study was anti- 
TNF-a (TCS Biologicals Limited, Buckingham, 
U.K.), diluted in 1:lOO rabbit serum in PBS. 
The slides were incubated overnight in a 
humidifying chamber at 4°C. Slides were 
washed in PBS and then incubated with 3% 
hydroxygen peroxide-methanol solution. After 
washing with PBS, the slides were incubated 
with secondary antibody (biotinylated mouse 
anti-rabbit, Dako Ltd.) for 1 h at room tem- 
perature, washed with PBS, incubated with 
avidin-biotin peroxidase complex (Dako Ltd.) 
for 30 min at room temperature, washed with 
PBS and then visualized with diaminobenzidine 
substrate (Dako Ltd.). The slides were counter- 
stained with Mayer’s Haematoxylin solution 
(Sigma Diagnostics, St. Louis, U.S.A.) for 
1 min. After washing and air-drying, the slides 
were scored on a quantitative basis by counting 
the number of positive (TNF-a stained) macro- 
phages. At least 100 macrophages were counted 
for each experimental condition, and results 
were expressed as percentage values. In control 
slides, the primary antibody step was omitted. 
Slides were coded and examined without 
knowledge of the code used in the experiment. 
TNF-a ELISA Assay 
TNF-a protein concentration in the superna- 
tants was determined by an ELISA kit (Human 
TNF Quantikine, R & D Systems, Oxon, U.K.). 
The absorbance (600 nm) of each well was 
determined with an automated plate reader 
(Dynatech Laboratory Ltd, Sussex, U.K.). The 
optical density was read in duplicate samples. 
The values for the standards were plotted vs. the 
concentration of the same standards, and the 
best curve was obtained. The data were linear- 
ized using regression analysis and presented as 
pug ml-‘. A regression analysis equation was 
used to determine the TNF-a concentration for 
each sample. 
In Situ mRNA Hybridization 
Slides were taken from - 8O”C, washed in PBS, 
dipped in 4% paraformaldehyde solution, 
washed again in PBS followed by acetylation 
with 0.1% acetic anhydride in 0.1 M tri- 
ethanolamine to reduce non-specific interaction 
between DNA probes and tissue. Slides were 
washed in PBS, air-dried and used for hybridiz- 
ation on the same day. A human TNF-a cocktail 
probe (R&D Systems, U.K.) was used. The 
labelling reaction consisted of 5 ,ul (5.8 p~pl- ‘) 
of oligonucleotides, 6 ~1 of terminal deoxynucleo- 
tide transferase (Amersham), 4~1 of reaction 
buffer, 7~1 of 35-S (dATP) (ICN Biomedicals) 
and 18 ~1 of distilled water to make a total of 
40~1. The reaction was incubated at 37°C for 1 h 
and labelled probes were purified using Nensorb 
20 nucleic acid purification cartridge (Nen Du- 
Pont Ltd., U.K.) according to the manufacturer’s 
recommendations. Slides were overlaid for 3 h 
with 400~1 of pre-hybridization solution which 
consisted of a 50% solution of formamide 
(Sigma), 1 ml 50 x Denhardt’s solution, 0.5 ml 
0.1 M ethylene diamine tetracetic acid (EDTA), 
lOOpug ml-’ denaturated salmon sperm DNA, 
25Opg ml-’ yeast t-RNA, 10 mM phosphate 
buffer, 10% dextran sulphate and 20 x sodium 
chloride/sodium citrate buffer. Before use, the 
solution was heated to boiling for 5 min, 
quenched on ice and 250 pug ml- ’ poly- 
adenylic acid and 10 mM dithiotreitol were added. 
The pre-hybridization solution was removed after 
3 h and the hybridization solution was over- 
laid on the slides. Hybridization solution was 
prepared diluting 35-S labelled probe in pre- 
hybridization solution to give between 20 and 
30 x 10 counts ml - ‘. Hybridization was per- 
formed overnight at 37°C. After incubation, the 
slides were washed using SSC at the following 
concentrations: 2 x SSC 1 h at room temperature 
with three changes, 1 x SSC 1 h at room tem- 
perature, 1 x SSC 30 min at 37°C and finally 
1 x SSC 30 min at room temperature. Following 
washing, slides were air-dried and dipped in 
Ilford nuclear track emulsion (Ilford Ltd 
Mobberley, Cheshire, U.K.). After an exposure 
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TABLE 1. Characteristics of patients studied 
Diagnosis 
Sex Mean age Smoking 
n M/F (years) yes/no 
Tuberculosis 12 913 41 418 
Sarcoidosis 3 l/2 38 013 
Lung cancer 5 213 65 5/O 
Chronic bronchitis 5 4/l 58 5/o 
Pneumonia 6 412 49 312 
Total 31 20/11 49 17/14 
period of 2 weeks, the slides were developed in 
Phenisol (Ilford Ltd.), dipped in 1% glacial acetic 
acid and 1% glycerol solution to stop developing 
reaction, fixed in 0.3 mol l- ’ sodium thiosul- 
phate (BDH Ltd, Poole, Dorset, U.K.), washed 
in distilled water, counterstained with Mayer’s 
Haematoxylin (Sigma) and mounted. The results 
were quantitated using the recognized method of 
counting the number of dots cell - ’ from 20 ran- 
dom alveolar macrophages (20). To corroborate 
these results, a second counting method was used 
in which the number of cells with more than 10 
dots cell - ’ out of 50 alveolar macrophages were 
counted. For controls, some slides were treated 
with RNase before adding TNF-a-labelled probe. 
Slides were coded and examined without 
knowledge of the experimental code. 
STATISTICAL ANALYSIS 
Data are presented as mean values f SEM. Com- 
parison between groups was performed with 
Wilcoxon’s test. A P value of less than 0.05 was 
considered significant. 
Results 
Thirty-one patients (Table 1) with a range of 
diseases associated with lung or airway inflam- 
mation (mean age =49 years; range = 22-8 1 
years; 20 men and 11 women; 17 smokers and 14 
non-smokers) were studied. 
Initially, results from macrophages from 
patients with a range of diseases including tuber- 
culosis were considered together. Following cul- 
ture for 24 or 48 h with LPS at 1 ,ug ml - ’ or 
10 lug ml - ’ [Fig. 1 (a,b)], there was an increase in 
cell-associated TNF-a in that there was a signifi- 
cant increase in the number of macrophages 
staining positively with antibody to TNF-a when 
compared to cells incubated in medium alone 
(PcO.05). The addition of either dexamethasone 
or thalidomide caused a significant reduction in 
the LPS-induced increase in the number of cells 
staining with antibodies to TNF-a such that in 
the presence of either of these drugs, the immu- 
nostaining was similar to that in cells incubated 
in medium alone (PcO.05). Similar results were 
observed when LPS was used at both 1 ,ug ml - ’ 
and 1Opg ml- ’ and for incubation periods of 24 
and 48 h (P<O*O5 in all cases). 
Similar results were observed for TNF-a 
secreted in culture supernatants, as measured 
using the ELISA assay (Fig. 2). Incubation of 
macrophages with LPS at ,ug ml - ’ for 24 h was 
found to increase TNF-a production signifi- 
cantly (P<O*O5), and the addition of dexametha- 
sone or thalidomide to cells incubated with 
LPS significantly reduced TNF-a production 
(P~0.05) to concentrations observed in super- 
natants from cells incubated with medium 
alone. 
The results from TNF-a mRNA measurement 
were similar to those obtained by TNF-a protein 
measurement. By both methods of counting 
{either the number of dots per cell [Fig. 3(a)] in 
20 random cells or the number of cells [Fig. 3(b)] 
with more than 10 dots}, a significant increase in 
TNF-a mRNA expression was observed when 
cells were incubated with LPS at 1 ,ug ml - ’ for 
24 h when compared to cells incubated with 
medium alone (P-43-05). The addition of either 
dexamethasone or thalidomide to cell cultures 
significantly reduced TNF-a mRNA expression 
to that observed in cells incubated with medium 
alone (P<O-05). The methodology discriminated 
TNF-a mRNA signal from carbon particles 
within macrophages of smokers and non- 
smokers. There was no significant difference in 
TNF-a mRNA expression by macrophages incu- 
bated with medium alone for 24 h when cells 
from smokers and non-smokers were compared 
either by the number of dots per cell in 20 
random cells or by the number of cells with more 
than 10 dots (P>O*O5). 
When results from patients with or without 
tuberculosis were compared, there were 
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FIG. 1. Percentage of macrophages stained with anti-tumour necrosis factor-a antibody following incubation 
for 24 or 48 h with medium alone (M), lipopolysaccharide (LPS) (L) at (a) 1 pg ml - ’ or (b) 10 pug ml - ‘, LPS 
plus dexamethasone (LD) or LPS plus thalidomide (LT). *P<O*O5. 
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FIG. 2. Concentration of tumour necrosis factor-u 
protein secreted by macrophages following incu- 
bation for 24 h with medium alone (M), lipopoly- 
saccharide (LPS) at 1 lug ml - ‘, LPS plus 
dexamethasone (LPS + DEX) or LPS plus thalido- 
mide (LPS+THAL). *P<O.O5. 
significant increases, following LPS treatment, in 
the number of macrophages staining positively 
[Fig. 4(a)] with antibodies to TNF-a (PcO.05) as 
well as in the expression of TNF-a mRNA [Fig. 
4(b)] by alveolar macrophages (PcO.05) in both 
groups of patients. Similarly, the addition of 
dexamethasone or thalidomide significantly 
reduced the number of macrophages staining 
positively with TNF-a antibodies [Fig. 4(a)] 
(P~0.05) and the expression of TNF-a mRNA 
by these cells [Fig. 4(b)] (P~0.05). This response 
to dexamethasone or thalidomide was similar in 
patients with or without tuberculosis. 
Discussion 
The main observation of this study was that 
thalidomide reduced LPS-induced TNF-a pro- 
duction by alveolar macrophages from patients 
with a range of lung diseases associated with 
airway or lung inflammation, including tubercu- 
losis. Thalidomide was observed to be as effec- 
tive as dexamethasone in reducing TNF-a 
production by alveolar macrophages, irrespec- 
tive of the diagnosis. This study extends previous 
observations (25) which found that thalidomide 
reduced TNF-a production by LPS-treated 
peripheral blood monocytes from normal 
volunteers. 
36 J. L. TAVARES EY AL 







FIG. 3. Tumour necrosis factor-u mRNA expression by macrophages following incubation for 24 h with 
medium alone (M), lipopolysaccharide (LPS) at 1 mg ml - ‘, LPS plus dexamethasone (LPS+DEX) or LPS 
plus thalidomide (LPS+THAL). The results were quantitated by counting either (a) the number of dots cell - ’ 
in 20 random cells, or (b) the number of cells with more than 10 dots out of 50 cells *P<O.O5. 
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FIG. 4. (a) Percentage of macrophages stained with anti-tumour-a antibody, and (b) TNF-a mRNA expres- 
sion by alveolar macrophages from patients with or without tuberculosis (TB) following incubation for 24 h 
with medium alone (M), lipopolysaccharide (LPS) at 1 ,ug ml - ’ (L), LPS plus dexamethasone (LD) or LPS 
plus thalidomide (LT). *P<O.O5. 
In the present study, alveolar macrophages 
were obtained from patients with a range of 
conditions including tuberculosis. Macrophages 
from all the patients, irrespective of diagnosis, 
had a similar response to thalidomide. There are 
limitations to grouping the data from patients 
with different diagnosis. However, this approach 
allowed samples from patients with tuberculosis 
to be compared with samples from a range of 
other lung diseases which might be expected to 
have resulted in in vivo priming of alveolar 
macrophages. It was hoped that by choosing 
such patients, the presence of ongoing inflamma- 
tion in the lungs of many of these patients would 
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serve as a priming stimulus, recognized to be 
important in TNF-a production by macrophages 
(13-16,18). Since similar results were observed 
when cells from patients with tuberculosis, a 
disease known to be associated with TNF-a 
production, and macrophages from patients 
with other diseases were compared, it is likely 
that thalidomide is effective in preventing the 
LPS-induced increase in macrophage TNF-a 
irrespective of the underlying disease. Human 
immunodeficiency virus (HIV) serology was not 
available in the patients in the present study for 
reasons of confidentiality. However, the marked 
increase in TNF-a production following LPS 
stimulation in cells from all subjects suggests 
that the knowledge of the HIV serology would 
not have altered the outcome of the study. 
In order to confirm that the effect of thalido- 
mide was manifest at the level of secreted pro- 
tein, non-secreted protein and mRNA, the 
combination of ELISA (Fig. 2), immunochemis- 
try [Fig. l(a,b)] and in situ hybridization [Fig. 
3(a,b)] was used. The effect of thalidomide was 
noted at different concentrations of LPS and 
duration of incubation, in that thalidomide was 
effective when added to cells stimulated with 
LPS at either 1 or 10,~g ml - ’ and incubated for 
both 24 and 48 h. A potential technical con- 
founding factor in this study was whether carbon 
particles in the alveolar macrophages from 
smokers might impede the in situ hybridization 
analysis. However, blind counts of hybridization 
signal in cells from smokers and non-smokers 
were similar, indicating this not to be the case. 
Although many stimuli cause macrophages 
to release TNF-a, including interferon-y, 
interleukin-2, colony stimulating factor-l, 
phagocytosis, binding of immunocomplexes, 
viral particles and Mycobacterium tuberculosis 
components (12,13,18,28), in the present study, 
the standard stimulus of bacterial LPS was used 
as the agonist to promote TNF-a production. 
The increase in TNF-a was noted at both 
mRNA and protein level, and this served as a 
model to assess drug effects. 
Thalidomide was first used in 1953 as an 
anti-convulsivant but it has been out of favour 
due to associated birth defects (24,29). Thalido- 
mide is a potent immunosuppressive agent in 
that it causes a reduction in mitogen-induced 
proliferation of peripheral blood monocytes 
as well as inhibition of neutrophil chemotaxis 
(30). Furthermore, thalidomide downregulates 
monocyte-specific surface markers as well as 
surface expression of integrin adhesion mol- 
ecules of lymphocytes, monocytes and granulo- 
cytes (30), and inhibits TNF-a production by 
mononuclear cells (14,25,27). This inhibition of 
TNF-a production by thalidomide depends 
upon the state of cell stimulation (25) and is 
reduced if thalidomide is removed prior to 
TNF-a induction (8). Kinetic studies with LPS- 
stimulated peripheral blood monocytes showed 
that thalidomide reduced TNF-a production 
when added some hours following LPS stimu- 
lation, raising the possibility that thalidomide 
acts at the post-transcriptional level by acceler- 
ating the degradation of TNF-a transcripts (26). 
Compared with thalidomide, corticosteroids 
have a different mechanism of action on TNF-a 
production by weakly inhibiting the accumula- 
tion of TNF-a mRNA and strongly inhibiting 
translation of TNF-a mRNA transcripts (31). It 
has been suggested that dexamethasone may 
have some effect on the LPS receptor itself or on 
the transducing protein involved in the response 
(31). In the present study, both thalidomide and 
dexamethasone were effective in reducing TNF-a 
production, although the exact mechanism was 
not investigated. 
This study did not measure concentrations of 
cytokines other than TNF-a. However, TNF-a is 
known to modulate other inflammatory medi- 
ators and its inhibition could lead to a reduction 
in the release of other molecules which, in vivo, 
might modulate the inflammatory reaction (27). 
Furthermore, TNF-a may play an important 
role in vivo in host resistance to infections as well 
as malignancies (32) arguing for the develop- 
ment of drugs to reduce but not totally inhibit 
TNF-a production. It is known that thalidomide 
concentrations used in this study (14pg ml - ‘) 
are similar to plasma concentrations obtained in 
man after the administration of a single oral 
dose of 150 mg of thalidomide, a dose which has 
been shown to be effective at reducing the symp- 
toms of erythema nodosum leprosum in leprosy 
patients (25). 
From the clinical perspective, this study pro- 
vided data that thalidomide at therapeutic con- 
centrations may reduce alveolar macrophage 
TNF-a production to a similar extent to that 
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occurring with corticosteroids. This may offer 
some clinical benefits and, in addition, may 
suggest a new avenue for the development of 
agents with action in reducing TNF-a pro- 
duction. Such an approach may offer some 
advantages over corticosteroids for the treat- 
ment of chronic inflammatory lung diseases, 
including tuberculosis, where TNF-a is thought 
to contribute to pathogenesis. 
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